N
Google TrendARSENAL (5000+) — Arsenal v Lille: Champions League – live
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:arsenal5000+anthony gordon500+montez sweat2000+rob lowe1000+tanner hudson500+frozen frenzy200+huevo1000+payton pritchard1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Novartis receives Europea" (30 stories)

Top Headline Story

Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
Lead StoryPharmaTimesworld
Jul 2

Novartis receives European Commission approval for Itvisma for spinal muscular atrophy

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPUHo2c1h4a1AxVGZwZUl2ZTQyYmFfcFduanpvVzBRV0V4YURoWkg5N0p0bS1WeVZidWw3bC1xUE10eWNBbFNqODdZdHZJRERRRzRraHZQaFgzOWdoMlY3UndaRTQyY1hJNjZSeXFqR0t2UzVLZmZxWWFWb2hHcHFiUVk4a29zcWgweTlKOU5EOFBUdmVjc1R4aU5TaUR0NV9oLTZENFdaS09DcDcyWEJQQkJUb3VFRFk?oc=5" target="_blank">Novartis receives European Commission approval for Itvisma for spinal muscular atrophy</a>  <font color="#6f6f6f">PharmaTimes</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+15m ago

arsenal

Arsenal v Lille: Champions League – live

Filter stories
500+15m ago

anthony gordon

Anthony Gordon's first Barcelona goal, Manuel Neuer's mistake and Djed Spence's Inter debut in the Euro Debrief

Filter stories
2000+25m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+35m ago

rob lowe

Ben Shapiro’s Star-Studded ‘Confession’ Film Includes James Franco, Rob Lowe And More

Filter stories

Search Results for "Novartis receives Europea"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Novartis receives European Commission approval for Rhapsido skin disease drug
Reutersworld

Novartis receives European Commission approval for Rhapsido skin disease drug

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPTnFZbFdYRmQ0UUl2N19tamVMbVNPZllkY2dZZkhFV3ZrLUFxUXZCaDk1bHUwWmRWcXpnUzVNNDNfVmNya1JFRjRmc0FRY243SGFFdUxyZ1NYWjlEUUtId2FheHd4aWlWYVc4cEg3NEZndWYzekdoVUVjMVJYaW9XdHIwZTRlY3JRYzR5NXNXMlQ5WDcxSEFMMmxKc2pFR213ZXcza3pqU1dSeWtBVVA4ZGNSUmVjVVVZQ19TVVFEUlVxcG10M3ZpNm84ZndBRVFqbnZjU1dVWlZsRmpHa2c?oc=5" target="_blank">Novartis receives European Commission approval for Rhapsido skin disease drug</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Yahoo Financeworld

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQR2RLRzJhMjlKUUZETWtnRDBYWGF4czQ0M0p3X0h3ZmYwVEpZNUw3VlhHSGx6MHJzWVhwZ0ZmZ3hoelZqV1VfZjRmUFZqQXVMWUtUOG0xTk9zS25nUXZjbkxBQnhadUx3LWRwLXI1dVB6WjFxWXh5ZU5TcmFVWVB0RGxONFNpMjJRS0xRSm9jaVRpQXlNdGJJcE9DeXZDcmF6ZVYxYUVYNEp0d2s?oc=5" target="_blank">Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Novartis to Layoff 322 NJ Employees: Report
Pharmaceutical Executivegeneral

Novartis to Layoff 322 NJ Employees: Report

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBFbFptTVAzVGMwQkNhaTRQVjVFY3h0eFZWYVFQbFJCem5HZGhpNWN0M1VSYjVqNmR1RHktT3JGS3Z6UG00dnVyTXV4T0ExZTNwYWRRc3gwaFV4dWNZb3RtZV8yZlBjaWFsdXU4NmpaT0U5cXRRUngtVFBn?oc=5" target="_blank">Novartis to Layoff 322 NJ Employees: Report</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Pharmaceutical Technologytech

Novartis secures pair of regulatory wins for skin disease and malaria treatments

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOT2JWdF9MM3hva2ROU0Z6MWctTWxkTm1NVHJBUU5rSm93MFVEQnY0RG16dFg0NThramZjRXB2QU1VblRDT2FMY0xfOHZRRDRXU09VdEFaZDdVODBESjdZS3Nxd2RwNVZZQk4waW5vUnF3bG5HT2x1dVhyUHhURVREakdwNEV0M0otZ1NKNUVCdTJtQUVucGIzWg?oc=5" target="_blank">Novartis secures pair of regulatory wins for skin disease and malaria treatments</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Yahoo Financeworld

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQVDlsRkZ3TzlSUmhITTRSRkUwV1JOVGxxMkhKNVpsTnJvekRqMDRWa3RKWUZfRVJGQV9YNVRnYXdXSGdiVkRxR1VYbEpkUzRISm54V0oyOUctdmNkMnF5bjRaM0dBRHVESlhuYVZCTEs4MmJRV240QkZsMUk3dDdLWS04WG9RYlRKX2dzQU4tVjhsNVBtVHpTVXFqZVdwTHpYei1lUUl4WkFYRkpvanBxdEk3ZDgwUQ?oc=5" target="_blank">Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Novartis Rhapsido® receives European Commission approval
GlobeNewswireworld

Novartis Rhapsido® receives European Commission approval

<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxPSGpxaDd3Qmk2eVM3TG9FUFJJNVhFdHJWZkJvNTl4Y3Y3a0Fkb0czZ0U0YVJBVlY5czE5al9yTkQwN0V0M3ozX29oVVA3WDIxTF90VTFWLU1mNmRWODNPdHFrd1B3cnVpbHZPMzRrdnczNzlBQ28yVFgzM3plaXRzcnhZcXJjVHBYWDlRNXltTjZqZGRCdm1oM0FSU3hqdGcwNUtrVlZIM0FRVV9LdkNUOTF3VXFrdkduaXpoRUFXbEZzSF9FR2FZMEF5dEZHcnBpWXBpTnhPU0YwZlZTT2tRV24taUlrVE5EUTVoczhMUXM4d05xLWJPTTN2aWRDQU1mM3FMN3RxRGpyN1N3bHZGNk9KWS1Qc0FQNTk2VE1Kcw?oc=5" target="_blank">Novartis Rhapsido® receives European Commission approval</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
CHMP backs drugs from Novartis, Crinetics while Vanda gets a thumbs down
FirstWord Pharmageneral

CHMP backs drugs from Novartis, Crinetics while Vanda gets a thumbs down

<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE9TTXlMcXM5c2Q3c2tMVm5LQ1A4c2dSZGFNNDc3b1lHMDFCbjlidnpJVDJzVkROVl9XV3p0dUU5dGdpOFRwUjdmZzFPbkZOVUdxT0Y0?oc=5" target="_blank">CHMP backs drugs from Novartis, Crinetics while Vanda gets a thumbs down</a>  <font color="#6f6f6f">FirstWord Pharma</font>

Read Full StoryMore like this
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
The Manila Timesgeneral

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOMTZRczR0RE5ndmtjNXdYclNPSmVtVHQ1M0ZVeHVYUmZpYXRHdWhsMTAwYmY5YXBYcXh6aS16VlFabFdPT3liQk9BZnhaeDg1a2l2VDVRRkJiRlI3S21PRFZyOHZtcHFwSnR6NjlVbmY5bEIwYnJwV0w2MUFzRWZBNHNHWjFueUw5QUxBeUMzdmVrLW5UWW43RzRKZHduNlBtODlodk9kVnQtQzJwazhUMDhxV2NUQXRsTmF4akRkYmpaaWVIczFKUVRSRDJJYzNxcXAyNkpjeFVXdDdDYUZOWFpqVjYtR0NFNlpuONIB8gFBVV95cUxOSGdNMk5neVc4RjdQcWxhUDJ0dnd0YXRxRGY1VU5UZldFczFMdXlVTEJFci1VTk9YYWVlV2I4WDFMX0dTSTl3V3QxSUFkUmFGOEx2d1lFeF9sT2FRYlpGUUpQWGJ6TXc4b0FfVXR3VFpxNXdQS19rUlRsQUNfOWlKSjZVSngwYUpPalJ3STRlal9TM1JoM0tkdnlORlJMY01ndG9sSU1WbmljNnlpWGJkY0JmWTB6b1FPVndOUk4yVFBidjMyS0E2RlNkYlY2QV9ZaVBGaXJCUzFKb0lRWWFNTmtfUjhCUDMzRWVEeHMxMXdFZw?oc=5" target="_blank">Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
PR Newswiregeneral

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

<a href="https://news.google.com/rss/articles/CBMi0AJBVV95cUxPY3kxenUxLUxITldtV1NoalhPbkFFU25qSUxzbDRoSFpjWWZQZXhWRWJPajB4V3h4RTMyajJUQXU5YWh4dEFiUEZsY0k0bkVFUGtHN1FYWU9CTGdRSVRjME9tVThDWnNvbmtzSlNaNWlWUG5HTnRJT3NTWEtPT2JEcE5iM0pESE1jai1jZ29aMnpxQWVLTUJJdTNTVHRSRGhuNUZZNXBaUnQ5eVpCdlNzN0p6QmU2aFV6MEN5Q1RWTUI5bXR5cFZqTnllSzkydDNUdHJJQXlobllNaVNObmdVYlU2NDZKM1ZQZlJYZkpjZElWS1dfSml0SGtsSWhWc2lYb2hKREJQMlJXUTcwQktDMjNsRjdRMlRvRHloVnk1SW9BVFRYUW93M1N1SGFSR1htNTh5ejNNVk0wRko2eVVkcERpSGJIeVNrWGp5WHVtdVU?oc=5" target="_blank">Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
The Pioneers of CAR-T Cell and Gene Therapy
Novartisgeneral

The Pioneers of CAR-T Cell and Gene Therapy

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxQY096V25CbUtaRkprM3lKNmM5aVhXTTBPdW96d2tENUpHWmp0LTdtajhoVmpZNE9wQjl2cW9JQVpmWldmZWtHZVB5dEwzYzdaaWdxbVBOVWFmWWlXWm5lYm5YSDdKN1NidFdPTDJMTmpUSXZfcktKa2IzYWpUbVdYWk45bUtWNktGc2pvSFlSbmVMRnNsRUpaQXVMSjctdDhnVHpoWHdFeHM2VFdIdE1mSTVfZFdFYXRWM2lrX1VQZ3Rsa1hXS1JTX3pQTFJycmQzZUdlQkJmTGdLQlRxcTlPSnBGZ0tsNl9kdVNwbjl4Tkpaa1ZMSFFPNE5FRFhyZmw5OGJnWDhEcTYyOEM1MXc?oc=5" target="_blank">The Pioneers of CAR-T Cell and Gene Therapy</a>  <font color="#6f6f6f">Novartis</font>

Read Full StoryMore like this
European Commission Approves Secukinumab for Hidradenitis Suppurativa
Dermatology Timesworld

European Commission Approves Secukinumab for Hidradenitis Suppurativa

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcG11c2xjM3hRbTBkV2xVX01ha2NYamxOR0IxWFNsZGZhN2lIZG5xa25zTmNGZTloaGZZdHVBR2lBUkRhQmJLMS1FZDVtR3pJSDd6RWU2SHlCcXRqcTVENFRfME0xWkluRXdVZ3F3VjlkM2FyYmhWN1JxcVVQbW96MTA0WkJrcFdYWjlZYW52bTc2YXhiNmZMcUc2a0JNM0s5MWNmM3VFTl9HWTA?oc=5" target="_blank">European Commission Approves Secukinumab for Hidradenitis Suppurativa</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
Novartis Receives European Approval for Beovu Anti-VEGF Treatment for Wet AMD
Eyewire+world

Novartis Receives European Approval for Beovu Anti-VEGF Treatment for Wet AMD

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxORlIzTFRQblhjTk0tai02clNhdUE5Y2NQZEF3LUhXUEREYTdqTFR0d01nd1FjY1BnTUFPcEVIN1dySWQ1eXhrWHBYOW1aR0VkaDNpeXNIZWhQeUVzMHpFOFJZV0FMbjlqVkJydVdMNHphMlRYeE1sNDM3R2wwLVZlRVRaTVJkX005RUtyN0pmSktwREZpT0FQN0dkT1ZNLXpNajZQajZR?oc=5" target="_blank">Novartis Receives European Approval for Beovu Anti-VEGF Treatment for Wet AMD</a>  <font color="#6f6f6f">Eyewire+</font>

Read Full StoryMore like this
Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies
Fierce Pharmaworld

Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPNHVRajJSM3lWd3JUcVROd2QwbWNvQlc1eHdTeGN5NmlNdVRsc0Z5bWNvYUlQakxBdDFJLVNBZWcyekQzWFBLam1iODlZSHRhTGZjQ19QZmV3anRDNnBlbjNST0d0dGpMSUJqZXByZFV2RmRzWjNjbmpyb0J0OWhCTnRMQmc2SEtKWEpUZEFTaE5fb3ZMeVJTRVZrT3pYUHJUZTM2SnhhdzM4c01iZ0E?oc=5" target="_blank">Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
Whistleblowers in Novartis Bribery Scandal Receive European Award
Whistleblower Network Newsworld

Whistleblowers in Novartis Bribery Scandal Receive European Award

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOFUxRlFWZXFqX1NCUGJKNzBlLWNwWXZ4VVVaR2t3NUd6RVFTMWhRXzNBZHgtMThHaG9abW55YXpDQ1JIYnFCaDVQQWE1ZE91MTBpajc5MmZHWVFQM3JBVmZPWXRqS3Q0ZDg1Mi1hWmhiVkRWbU9jZ2JKVkhVemQ1QUtSVzNTSTRrZk1qbUVOanRRMUpHS0otS1hUaGxXanU5cWUyUVBIMjJrd9IBqgFBVV95cUxNOFUxRlFWZXFqX1NCUGJKNzBlLWNwWXZ4VVVaR2t3NUd6RVFTMWhRXzNBZHgtMThHaG9abW55YXpDQ1JIYnFCaDVQQWE1ZE91MTBpajc5MmZHWVFQM3JBVmZPWXRqS3Q0ZDg1Mi1hWmhiVkRWbU9jZ2JKVkhVemQ1QUtSVzNTSTRrZk1qbUVOanRRMUpHS0otS1hUaGxXanU5cWUyUVBIMjJrdw?oc=5" target="_blank">Whistleblowers in Novartis Bribery Scandal Receive European Award</a>  <font color="#6f6f6f">Whistleblower Network News</font>

Read Full StoryMore like this
Novartis wins approval for first malaria drug for newborns and babies
Reutersgeneral

Novartis wins approval for first malaria drug for newborns and babies

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeVV1Qm1UcHdjbTJiRzc2NUJqb21ndTN5T3hjdVZ4N3k0UlNoQ2FmM2lWSXB6ZTU5eGIwTDBxaGVWQkhSYW5ZQTdDZmFaR2xIZ3MxeENxb291RDBHSVhQX2c1YjY5LWEtRXFhV3o1dmNzYWNRNXNBRFB6V3VXdThlc1hNR0VxSHpMWGZmbk9lUGxyRERtc2dYLVl6OXRDeDh5VWJVQ0hFRU51X2pUOHdkM2RQWU1QTXVKbFVXTk9YVXVDSlQ4eW9mSQ?oc=5" target="_blank">Novartis wins approval for first malaria drug for newborns and babies</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
European Commission approves Novartis’ Itvisma to treat SMA
Pharmaceutical Technologyworld

European Commission approves Novartis’ Itvisma to treat SMA

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOaUJXZDl1dXNvSjYxMTFiNzRmTmlCQVViajBGcWFFVjFFZS1aWHZOV0ZPeFBzdmpVTm56NXYyeDM1YnFndFNHS0twRVd0MjNDMzdGU2ZzS3c0VDlEM3ZPQUtfUE1PNG5oN280ZHdEanF5bjJNOF9XTW1FejdmLUpzT2lqelBVbU5UalhLb1M1anhrcnFselVTcA?oc=5" target="_blank">European Commission approves Novartis’ Itvisma to treat SMA</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval
Pharmaceutical Executivegeneral

Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQVUdoVWpQWkhLVUlHRFhNeGtJb3g0VHNScWZLdTN4ZHBhelIxM3hla2xwUUphbGl2QlJYZmxrUFlyRmhTcEZKQ2tqZWxWaW1HVGdFQ0FFcGR4ZU13NEZFY1pMcnNzazl2dHpRSXI0bEZvRmh0bTFVMDNuU0JSdGtUMkhaV2FzZUFLNVplT3lLNG1oSTdON2NMandfNmd4Uldxb0kwZjRrQkUwSjlsMUdJ?oc=5" target="_blank">Novartis’ Chronic Spontaneous Urticaria Treatment Rhapsido Receives FDA Approval</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Yahoo Financegeneral

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOdkw3Y2dnR1hIYUVsUUQxSk84N3pPNkVQRWstZjROSk1uaXBheUtEbHVkcktaUHFsTE53QmdLV0RvWk12cmV3aU04aG5TS0piV2IxNk83RXBFa3Z2aUNNSlBkYkg0THJTRXhIc0tPZ1Z2ZFpGZi1xcnJFRnJ6ZVdLNkgtY2ZFTjZCYUN6QzFVRk9IRVJIOWlHVHhhMjNiY1pvTENicG9fNA?oc=5" target="_blank">Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
US FDA expands use of Novartis drug for chronic skin condition
Yahoo Financegeneral

US FDA expands use of Novartis drug for chronic skin condition

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNR2VsN3lNbDFDT19qQzF6R0FxUWFVQ2ZSQl8xQVA0NjljM3B1blVUcWdoMnZaby0xWXFhRjQxRFVydHhOQmhaSU9aX1d0RGNWQ3hWemN2ano5Tl9oNjE3dHJUMWkzTC1FYUpsLTVucHlOQnV4OGxUN0N3Y1VHcXpkdURiMzFnMnZGR1M3VW9hV1FsQlk?oc=5" target="_blank">US FDA expands use of Novartis drug for chronic skin condition</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Novartis gets EU approval for potential blockbuster cholesterol drug Leqvio
Reutersgeneral

Novartis gets EU approval for potential blockbuster cholesterol drug Leqvio

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOUjE2X1BaMDVPeGo5ZkswZ1hraDM0a09DbjNqUDBIY2poeDVpdFB2M2YyRV9iWTlLQU43dHBfYW1QZXBjQ0RMQVYzOGQwUDRlcWxuX1lsZDExWEc2V1JyeXdiX05Qb1JQVUpVY2NMdUlwRldLVU4tZkZFRWtFRnV4ajlDOVR6aUJVV050UlVBOVpHZUZXT3dWdUZyWmRrOEdaMWZEdXNvNmxqVURSR2Z0SC1sdjVWb0tFUGllRy1PLVE5RXJ0UmZpRF94bFpPeXBPcmJHN1VaOUVWaW8?oc=5" target="_blank">Novartis gets EU approval for potential blockbuster cholesterol drug Leqvio</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Novartis scores Phase III wins for two ianalumab indications
European Pharmaceutical Reviewgeneral

Novartis scores Phase III wins for two ianalumab indications

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQZzNneERuMHNhUVpKbUozY2ZNeWdTYkd0bGVHdnFXTV9udTBHNjFFR3NTdmJyYi15WXB5RjlENEZhYnFwdFA0aHY5RmRmek1yTTRNQ2t1eUZzdk5SMURPSjRnbnFZYi1tQ3p5bWxPTHozdzNYQllzZUdHSFhJN1JuNzg3MkF5akFaVUdWRFZFZWVqNk1MRnQ5WklGTXBRbkU3eVJCNEY3c0dkeGpna1V4Qk9Zbnk4elAtQnRqakZ0eHhaMzA?oc=5" target="_blank">Novartis scores Phase III wins for two ianalumab indications</a>  <font color="#6f6f6f">European Pharmaceutical Review</font>

Read Full StoryMore like this
Novartis' Kymriah gets European approval to treat two cancers
Pharmaceutical Technologyworld

Novartis' Kymriah gets European approval to treat two cancers

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQSXFYVXNlWEtmcHA4a3FvdzhIR2FRRThPaVVSOEFXRlY0LW1EMmNVbVo0UzgxWGlRcDVKWGxBeFR2NFZEcThlSmlIZFRVa215eW1oVFkwaGhqRVJRTm5yUTNMZndzakJPUnlkZk1aT1R6MDFHNjEwMjZ5RVJkcGVsODNXV2s1Ui1qcTRtVVJDNGhVbXlFS21waU9n?oc=5" target="_blank">Novartis' Kymriah gets European approval to treat two cancers</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Novartis gets European approval for psoriasis drug Cosentyx
Reutersworld

Novartis gets European approval for psoriasis drug Cosentyx

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPQWJiUE1GUm1zV3U5bEplTmZMQU50Ny1heU12cWp1a2hPc3ZIRWJka18zbmMxb2xGOGlkR3lzQzNqek1DZGtTSm1EdG1OcXduUWUxTWtEZjNXTExiQ05mX1NGN3ExVmg4ellOSklvR29TTy1rZElEa01Wdm4zWE5oeGxDVWpEdWtNUHFLdmJwcmxGRHVFbXdRV29NMU4tVUlaQnRBNWRTTE5pLW5OeWZwejczUHFfZw?oc=5" target="_blank">Novartis gets European approval for psoriasis drug Cosentyx</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Novartis Kisqali Receives European Commission Approval for HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Oncodailyworld

Novartis Kisqali Receives European Commission Approval for HR+/HER2- Early Breast Cancer at High Risk of Recurrence

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE1DcUp0eEpyVE9GWUphNDB5bWlJNjhacy01TGlVcF9QSlZNUDF4TTdoNkJLMFh6MFE5YlptWE9SVTc2eW45OUprT1B2cUpPUUdCRTdSWlJia1NyRE00ekE3Mm9lSQ?oc=5" target="_blank">Novartis Kisqali Receives European Commission Approval for HR+/HER2- Early Breast Cancer at High Risk of Recurrence</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts (NYSE:NVS)
Seeking Alphageneral

Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts (NYSE:NVS)

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQa2xzUUYtRDh1RkpyNThGbHVFeU5oRGVfRUdIU21WRTRZNTFKWnd0VWREcGM3SEJoWG91VVZwU2lGT0NQU1g3SjdhTTR3NHpRQVRvYUJJeWRsV05EWk9CVUl2anpiSjJxVVM1X05sRmtQVmN4b3FXZWxGX1dMbTNNS3Z1b0FNMThJTlk4cFFTcjBqWDFGZFBGclJPd1ZpNk14bGtSWnBycHJfUEY0M2ljUmtZaDVpYUE?oc=5" target="_blank">Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts (NYSE:NVS)</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
Sandoz' MS drug receives approval from European Commission
Reutersworld

Sandoz' MS drug receives approval from European Commission

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQQmt1WXg2VmxNVjdYUjBqanNfX3dRTFJoclQ4czVYVmV3V3VCT3YtY1FVa0dCUzU3eGVKUUYyMDRPcWJYYm9ZOVVsUzVLbVRBRzU4bDY3eGlBT3pWUklqVm5MaGZlYmU3VV9Rc3RiSVRESEVDNVpNVktqWnQ3ck1Pdy1odEVuVUw2QmhsV0EyZzdOcWk1TUF2MmZQUWQ5WnhNa3ZkNE5SRDdVbFlDQm5abDRWRFc2YWZNT0RMdk92b0Rzdw?oc=5" target="_blank">Sandoz' MS drug receives approval from European Commission</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
MedCity Newsgeneral

Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMktWb0N6NmtDcFFYakNLREQ2eG5WME5lal82V0trXy1SSENHZG9xSmFJTmFtY296YWVFbEEwZjNITEhWZnBYSjZ6RGVzY1M2QTNBU0xVVkU1YkFJZnNVbi1rSjBDV1NOOUt5N0tqQTJOV0l6UVRMVnJtTmNrUEtZMmpQVzNFY2lQU0pmSVVDM24zU2J3Qm5yTDgzanYyZWs1TVFMWjNsVUktUXFpajFvT1BIX3YyNC1oUG81bGV0Y1c?oc=5" target="_blank">Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies</a>  <font color="#6f6f6f">MedCity News</font>

Read Full StoryMore like this
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Yahoo Financegeneral

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNMlIwQVZ2ZWNTNjlZd1pfYjdBVVB3YVN6eUprc0czckRlOVJyZzNVSG9rVzFDeURNZzFaSmxTY0xwZGppdWRCNW4wOTlGc3Zlam43dHNULVc0UnJ4cEN5TXhXYllka1dlVVNaWTVmTzVLN2RFSVNfdTJTci1KOG4yNmotUTVMZzZIeFN4cG52elN3TGRJRktqSTBIaXFIUDdrTVE?oc=5" target="_blank">Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
European Commission Approves 177Lu Vipivotide Tetraxetan Plus ADT for Prostate Cancer Subset
CancerNetworkworld

European Commission Approves 177Lu Vipivotide Tetraxetan Plus ADT for Prostate Cancer Subset

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOUGtjamdBYl9RbDh5MjkxeXE1TElJNkgycFBrejR4c2tIUW5SUWJ6c05BSXBSLXdUUmJfaVZhV1dtclFBc2lTcFZubWtCVjc4dlU4RFJiblNBVUNxRWo5VU15V3RGMDV5X0gwaWRCRGotNGxDQmZTMTdIejBpMUdqckxLZW5GUk53SWdCdEZfWjZpSF9aamsxWHJUd0w1dWxUd242OWVSaGh6ZWk1ckdsQkVXLTB6N0pNMDg0YzMtQWpWdVh4S1E?oc=5" target="_blank">European Commission Approves 177Lu Vipivotide Tetraxetan Plus ADT for Prostate Cancer Subset</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"Novartis receives Europea" — Live Google News Trends & Headlines